Effect of the novel galectin-3 blocker, Gal3M, on the efficacy and reduction of toxicity of proteasome inhibitors for the treatment of multiple myeloma

Autor:	Saba Radhi, Jose A. Figueroa, Amardeep Aulakh, Fred Hardwick, Michela Colombo, Scott Dahlbeck, Rashmi Verma, Leonardo Mirandola, Jehanzeb Riaz, Kayley Trotter, Diane Duyen Thuy Nguyen, Maurizio Chiriva-Internati, Fabio Grizzi, Marjorie R. Jenkins, Yuefei Yu, Venu Madhav Konala, Everardo Cobos, Nicholas D'Cunha, Lukman Aderoju Tijani
Rok vydání:	2014
Předmět:	Cancer Research Anemia business.industry medicine.disease Oncology Proteasome Neoplastic Plasma Cell Galectin-3 hemic and lymphatic diseases Toxicity medicine Cancer research business Multiple myeloma
Zdroj:	Journal of Clinical Oncology. 32:e19581-e19581
ISSN:	1527-7755 0732-183X
Popis:	e19581 Background: Multiple myeloma (MM) is a neoplastic plasma cell disorder which results in multiple organ failure. Anemia, hypercalcemia, renal failure and skeletal lesions are the most relevan...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5d9c848d8cf73d7f9293d483617952ab https://doi.org/10.1200/jco.2014.32.15_suppl.e19581 Zobrazit plný text záznamu